ClinicalTrials.gg
CompletedNCT00567190CLEOPATRAUpdated Dec 13, 2019Results posted

A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer

A Phase 3 interventional study of Pertuzumab and Placebo in Metastatic Breast Cancer, sponsored by Genentech, Inc.. Completed at 322 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-13.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
808
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 104 studies testing pertuzumab in Breast Neoplasms — 26 open to participants now, 45 under way, 7 of them phase 3. pertuzumab · Breast Neoplasms.

Enrollment
10th of 104
808 · median 100
Started
2008
the only one that year
Phase 3
23 of 104
2 open now
Registered
3rd of 104
by date
Lead sponsor
2 of 104
Genentech, Inc.

Among the 104 studies testing pertuzumab in Breast Neoplasms, this one is the 10th largest by enrollment, is the only one that started in 2008, is one of 23 in phase 3, and was the 3rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

26 of the 104 studies testing pertuzumab in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

21 more — sign in →

By country, each count listing its studies:

All 26 open studies →

About pertuzumab

pertuzumab: first FDA approval 2012 (PERJETA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing pertuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This study was a Phase III, randomized, double-blind, placebo-controlled, multicenter international clinical trial conducted to investigate the use of pertuzumab in combination with trastuzumab and docetaxel as first-line treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). Participants could have received one prior hormonal treatment for MBC. Participants may have received systemic breast cancer treatment in the neo-adjuvant or adjuvant setting, provided that the participant had experienced a disease-free interval (DFI) of greater than or equal to (≥)12 months from completion of adjuvant systemic treatment (excluding hormonal therapy) to metastatic diagnosis. Participants may have received trastuzumab and/or a taxane during the neo-adjuvant or adjuvant treatment.

Participants were randomized in 1:1 ratio to receive either pertuzumab or placebo, along with trastuzumab and docetaxel once every 3 weeks (q3w), during the treatment phase of the study until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination. Participants in the Placebo arm were not allowed to receive open-label pertuzumab after discontinuation from study treatment. However, if any analysis of overall survival had met the predefined criteria for statistical significance, participants in the Placebo arm still on treatment were offered the option to receive open-label pertuzumab in addition to other study medications.

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

Keywords

  • Herceptin
  • Breast cancer
  • MBC
  • Taxotere
  • HER2
  • HER2 positive breast cancer
  • HER2 + breast cancer
  • HER2-positive
  • HER2-positive metastatic breast cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed adenocarcinoma of the breast with locally recurrent or disease, and candidate for chemotherapy. Participants with measurable and non- are eligible (locally recurrent disease must not be amenable to resection with curative intent; participants with de novo Stage IV disease are eligible)
  • Human epidermal growth factor receptor 2 ()-positive metastatic breast cancer (MBC)
  • (LVEF) ≥50 percent (%) at baseline (within 42 days of randomization)
  • (ECOG) performance status (PS) 0 or 1
  • For women of and men with partners of childbearing potential, agreement to use a highly effective form of and to continue its use for the duration of study treatment and for at least 7 months after the last dose of study treatment

Exclusion criteria

Exclusion Criteria:

  • History of anti-cancer therapy for MBC (with the exception of one prior hormonal regimen for MBC, which must be stopped prior to randomization)
  • History of approved or investigative tyrosine kinase/HER inhibitors for breast cancer in any treatment setting, except trastuzumab used in the or adjuvant setting
  • History of systemic breast cancer treatment in the neo-adjuvant or adjuvant setting with a disease-free interval from completion of the systemic treatment (excluding hormonal therapy) to diagnosis of less than (\<)12 months
  • History of persistent Grade ≥2 hematologic toxicity resulting from previous adjuvant therapy
  • Current peripheral neuropathy of National Cancer Institute- (NCI-CTCAE) Version 3.0, Grade ≥3 at randomization
  • History of other within the last 5 years, except for carcinoma in situ of the cervix, basal cell carcinoma or squamous cell carcinoma of the skin that has been previously treated with curative intent
  • Current clinical or radiographic evidence of central nervous system (CNS) metastases
  • Computed tomography (CT) or magnetic resonance imaging (MRI) scan of the brain is mandatory in cases of clinical suspicion of
  • History of exposure to cumulative doses of anthracyclines
  • Current uncontrolled hypertension or unstable angina
  • History of congestive heart failure (CHF) of any (NYHA) criteria, or serious cardiac arrhythmia requiring treatment (exception: atrial fibrillation or paroxysmal supraventricular tachycardia)
  • History of myocardial infarction within 6 months of randomization
  • History of decline to below 50% during or after prior trastuzumab neo-adjuvant or adjuvant therapy
  • Current dyspnea at rest due to complications of advanced malignancy, or other diseases that require continuous oxygen therapy
  • Inadequate organ function, as defined in the protocol, within 28 days prior to randomization
  • Current severe, uncontrolled systemic disease
  • Major surgical procedure or significant traumatic injury within 28 days prior to study treatment start or anticipation of the need for major surgery during the course of study treatment
  • Pregnant or lactating women
  • History of receiving any treatment within 28 days of randomization
  • Current known infection with (HIV), virus (HBV), or virus (HCV)
  • Receipt of IV antibiotics for infection within 14 days of randomization
  • Current chronic daily treatment with (excluding inhaled steroids)
  • Known to any of the study drugs
  • Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
808 participants (actual)

Study arms

  • Experimental
    Pertuzumab + Trastuzumab + Docetaxel

    Participants randomized to this arm received pertuzumab 420 milligrams (mg) intravenously (IV) once every 3 weeks (q3w) and trastuzumab 6 milligrams per kilogram (mg/kg) IV q3w, plus docetaxel 75 milligrams per square metre of body surface (mg/m\^2) IV q3w (for at least 6 cycles; 1 cycle was 21 days). After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician. Participants remained in the treatment phase of the study until investigator-assessed radiographic or clinical evidence of disease progression, unmanageable toxicity, or study termination and were followed for survival until death, loss to follow-up, withdrawal of consent, or study termination.

    Drug: Pertuzumab · Drug: Trastuzumab · Drug: Docetaxel

  • Placebo comparator
    Placebo + Trastuzumab + Docetaxel

    Participants randomized to this arm received placebo IV q3w and trastuzumab 6 mg/kg IV q3w, plus docetaxel 75 mg/m\^2 IV q3w (for at least 6 cycles; 1 cycle was 21 days). After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician. Participants remained in the treatment phase of the study until investigator-assessed radiographic or clinical evidence of disease progression, unmanageable toxicity, or study termination and were followed for survival until death, loss to follow-up, withdrawal of consent, or study termination.

    Drug: Placebo · Drug: Trastuzumab · Drug: Docetaxel

Interventions

  • Pertuzumab was administered as an intravenous (IV) loading dose of 840 milligrams (mg) q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 420 mg q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.

    Also known as: Perjeta, RO4368451, RG1273

  • DrugPlacebo

    Placebo (matching pertuzumab) was administered intravenously.

  • Trastuzumab was administered as an IV loading dose of 8 milligrams per kilogram (mg/kg) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 6 mg/kg q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.

    Also known as: Herceptin

  • Docetaxel was administered as an IV dose of 75 milligrams per square meter of body surface area (mg/m\^2) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 75 mg/m\^2 (up to 100 mg/m\^2 as per treating physician discretion) q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination. On or prior to Cycle 6, docetaxel was only to be discontinued for progressive disease or unmanageable toxicity. After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician.

    Also known as: Taxotere

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) Determined by an Independent Review Facility

    PFS was defined as the time from randomization to first documented radiographical progressive disease (PD), as determined by an independent review facility (IRF) using RECIST version 1.0, or death from any cause (within 18 weeks of last tumor assessment), whichever occurred first (Kaplan-Meier method). For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum of the LD recorded since treatment started or the appearance of ≥1 new lesion. For non-target lesions, PD was defined as the appearance of ≥1 new lesion or unequivocal progression of existing lesions. Participants without IRF-determined PD or who had not died within 18 weeks of their last IRF-determined, progression-free tumor assessment were censored at the date of the last IRF-reviewed, evaluable tumor assessment; those with no post-baseline tumor assessment and who had not died within 18 weeks of baseline were censored at 1 day.

    Time frame: Tumor assessments every 9 weeks from randomization to IRF-determined PD or death from any cause, whichever occurred first, up to the primary completion date (up to 3 years, 3 months)

Secondary outcomes

  1. Overall Survival

    Overall survival (OS) was the time from randomization to death from any cause, using Kaplan-Meier methodology. Survival data was collected every 18 weeks during the post-treatment follow-up period until death, loss to follow-up, or withdrawal of consent. Those who were alive, lost to follow up, or withdrew consent were censored at the latest date they participated in the study; those without post-baseline data were censored at 1 day. OS analyses were planned to take place at the primary completion date (First Interim), after 385 deaths (Event-Driven Final), and at the end of study (End-of-Study). A second interim OS analysis was planned due to a formal request from the European Medicines Agency. Median \[range\] time in weeks on study at each OS analysis (Pertuzumab vs. Placebo): First: 77.1 \[0.7-165.3\] vs. 73.1 \[0.4-165.3\]; Second: 117.1 \[0.7-207.9\] vs. 105.9 \[0.4-207.9\]; Event-Driven Final: 189.9 \[0.7-304.1\] vs. 140.5 \[0.4-301.6\]; End-of-Study: 201.8 \[0.7-520.0\] vs. 138.0 \[0.4-514.7\].

    Time frame: From randomization to death from any cause, up to each respective analysis data cut-off date (see the Description field for the median time on study per treatment arm)

  2. Progression-Free Survival (PFS) Determined by the Investigator

    PFS was defined as the time from randomization to first documented radiographical progressive disease (PD), as determined by the investigator using RECIST version 1.0, or death from any cause (within 18 weeks of last tumor assessment), whichever occurred first (Kaplan-Meier method). For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum of the LD recorded since treatment started or the appearance of ≥1 new lesion. For non-target lesions, PD was defined as the appearance of ≥1 new lesion or unequivocal progression of existing lesions. Participants without PD or who had not died within 18 weeks of their last investigator-determined, progression-free tumor assessment were censored at the date of the last investigator tumor assessment; those with no post-baseline tumor assessment and who had not died within 18 weeks of baseline were censored at 1 day.

    Time frame: Tumor assessments every 9 weeks from randomization to investigator-determined PD or death from any cause, whichever occurred first (median [range] time on study in pertuzumab vs. placebo arms: 201.8 [0.7-520.0] weeks vs. 138.0 [0.4-514.7] weeks)

  3. Objective Response Determined by an Independent Review Facility

    An objective response was defined as the percentage of participants with confirmed best overall response of complete response (CR) or partial response (PR) determined by an independent review facility (IRF) using RECIST v1.0 on two consecutive occasions ≥4 weeks apart. For target lesions, CR: disappearance of all target lesions; PR: ≥30% decrease in the sum of the longest diameter (LD) of target lesions (baseline sum LD as reference); PD: ≥20% increase in the sum of the LD of target lesions (smallest sum of the LD recorded as reference) or appearance of ≥1 new lesion; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase for PD. For non-target lesions, CR: disappearance of all non-target lesions; Incomplete/SD: persistence of ≥1 non-target lesions; PD: unequivocal progression of existing non-target lesions. 95% confidence intervals (CI) were calculated only for clinical responses using the Pearson-Clopper method.

    Time frame: Tumor assessments every 9 weeks from Baseline until IRF-determined progressive disease (PD), death, or first administration of next line of anti-cancer therapy (whichever occurred first), up to the primary completion date (up to 3 years, 3 months)

  4. Duration of Objective Response Determined by an Independent Review Facility

    Duration of objective response (estimated using the Kaplan-Meier method) was defined as the time from the initial confirmed complete response (CR) or partial response (PR), the date of tumor assessment at which the CR/PR was first detected by the independent review facility (IRF) using RECIST version 1.0, until the date of IRF-determined progressive disease (PD), death from any cause within 18 weeks of the last tumor assessment, or first administration of next line of anti-cancer therapy (whichever occurred first). If the visit when the initial CR or PR was observed spanned multiple dates, the latest date was used. Only participants in the ITT analysis population with an IRF-determined objective response (CR or PR), observed prior to IRF-assessed PD, death or next line of anti-cancer therapy, were included in the analysis. Participants who did not progress or die after they had a confirmed response were censored at the date of their last IRF-evaluable tumor measurement.

    Time frame: From initial IRF-confirmed objective response until IRF-determined progressive disease (PD), death, or first administration of next line of anti-cancer therapy (whichever occurred first), up to the primary completion date (up to 3 years, 3 months)

  5. Time to Symptom Progression

    Time to symptom progression was defined as the time from randomization to the first symptom progression as measured by the Functional Assessment of Cancer Therapy-for patients with Breast Cancer (FACT-B) questionnaire with the Trial Outcomes Index-Physical/Functional/Breast (TOI-PFB) subscale. The FACT-B TOI-PFB subscale contains 24 items from 3 subsections of the FACT-B questionnaire: Physical well-being, functional well-being, and additional concerns for breast cancer patients (breast cancer subscale \[BCS\]). All items in the questionnaire were rated by the patient on a 5-point scale ranging from 0 ("not at all") to 4 ("very much"). The total score ranged from 0 to 96. A higher score indicates better perceived quality of life. A positive change score from baseline indicates improvement. Symptom progression was defined as a decrease from baseline of 5 points or more.

    Time frame: Every 9 weeks from Baseline until investigator-determined progressive disease, up to the primary completion date (up to 3 years, 3 months)

  6. Overall Number of Participants Who Experienced at Least One Adverse Event, Including Serious and Non-Serious Adverse Events, by Most Severe Intensity (According to NCI-CTCAE v3.0) During the Treatment Period

    Adverse event (AE) severity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0 (NCI-CTCAE v3.0); if the AE was not specifically listed, the following grades of severity were used: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening or disabling; and Grade 5 = death. Severe and serious are not synonymous. Severity refers to the intensity of an AE, whereas a serious AE must meet criteria set out in the protocol; both were independently assessed for each AE. Only the most severe intensity was counted for multiple occurrences of the same AE in one participant. AEs reported prior to first crossover treatment were included in the Placebo arm, and in the Crossover arm after that date, for participants who crossed over from placebo to pertuzumab. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks.

    Time frame: Placebo arm: Baseline to last dose of study treatment +42 days (or crossover date); Pertuzumab arm: Baseline to last dose of study treatment +42 days; Crossover arm: Crossover date to last dose of study treatment +42 days (see Description - time per arm)

  7. Overall Number of Adverse Events by Severity (NCI-CTCAE v3.0 All Grades and Grades 3 to 5) Per 100 Patient-Years of Exposure During the Treatment Period

    Adverse event (AE) severity, including serious and non-serious AEs, was assessed according to the NCI-CTCAE version 3.0; if the AE was not specifically listed, the following grades of severity were used: Grade 1 is mild; Grade 2 is moderate; Grade 3 is severe; Grade 4 is life-threatening or disabling; and Grade 5 is death. Multiple occurrences of the same AE in 1 participant were counted multiple times. Only AEs that started during the overall study treatment period were included. The cutoff date for inclusion of events and for calculation of patient-years was the date of the most recent follow-up of the participant, defined as the last available date during the treatment period, excluding pre-treatment and safety follow-up data. Confidence intervals were calculated assuming the number of events followed a Poisson distribution. Data reported prior to the date of first crossover treatment were included under the Placebo arm for participants who crossed over from placebo to pertuzumab.

    Time frame: From Baseline to 42 days after the last dose of study treatment (total patient-years of exposure on study treatment in Placebo vs. Pertuzumab arms: 526.81 vs. 989.88 patient-years)

  8. Cardiac-Related AEs to Monitor: Number of Participants Who Experienced at Least One Symptomatic Left Ventricular Dysfunction (LVD), Any LVD, or Serious AE Suggestive of Congestive Heart Failure by Severity During the Treatment Period

    Cardiac-related adverse events (AEs) to monitor during the study included investigator-assessed symptomatic left ventricular dysfunction (LVD), any LVD, or a serious adverse event (SAE) suggestive of congestive heart failure (CHF). All cardiac-related AEs were graded for severity according to NCI-CTCAE v3.0. Asymptomatic (Grades 1-2) and symptomatic (Grades 3-5) left ventricular systolic dysfunction (LVSD) both coded to the MedDRA preferred term LVD. Investigator-assessed events of symptomatic LVD were also graded for severity of symptoms according to Classes I (least severe) to IV (most severe) of the New York Heart Association (NYHA) Classification. SAEs suggestive of CHF were identified as serious events from the Standardized MedDRA Query (SMQ) (Wide) 'Cardiac Failure'. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks.

    Time frame: Placebo arm: Baseline to last dose of study treatment +42 days (or crossover date); Pertuzumab arm: Baseline to last dose of study treatment +42 days; Crossover arm: Crossover date to last dose of study treatment +42 days (see Description - time per arm)

  9. Number of Participants Who Experienced at Least One Adverse Event to Monitor (Excluding Cardiac-Related AEs) by Severity During the Treatment Period

    The clinical diagnoses listed in this table, excluding cardiac safety (summarized separately), were also selected as adverse events (AEs) to monitor based on clinical and nonclinical data for pertuzumab and the safety profile established for trastuzumab, monoclonal antibodies in general, and potential effects associated with HER receptor inhibition. Search strategies were defined by single or aggregate MedDRA Preferred Terms (PT) through Standardized MedDRA Queries (SMQ), where possible, or based on Roche AE Group Terms (AEGT). Diarrhoea AEs: High-Level Term (HLT) 'Diarrhoea (excl. infective)' and PT 'Diarrhoea infectious'. Leukopenic and Febrile Neutropenic Infections: AEs from 'Infections \& Infestations' with start ≤14 days after start date of Grade ≥3 AEs in SMQ(narrow) 'Leukopenia' or PT 'Febrile neutropenia', respectively. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks.

    Time frame: Placebo arm: Baseline to last dose of study treatment +42 days (or crossover date); Pertuzumab arm: Baseline to last dose of study treatment +42 days; Crossover arm: Crossover date to last dose of study treatment +42 days (see Description - time per arm)

  10. Overall Number of Participants Who Experienced at Least One Adverse Event Leading to Discontinuation of Any or All Study Medication

    Participants could continue study treatment with pertuzumab/placebo plus trastuzumab when docetaxel was discontinued due to an adverse event (AE). Discontinuation of pertuzumab/placebo or trastuzumab due to an AE led to discontinuation of all study medication. The number of participants who discontinued any study medication due to an AE includes those who discontinued all study medication and those who discontinued docetaxel only and then continued on targeted therapy (note: some of these participants may have subsequently discontinued all treatment due to a separate AE). Multiple occurrences of the same adverse event in 1 participant was counted only once. AEs reported prior to first crossover treatment were included in the Placebo arm, and after that date in the Crossover arm, for those who crossed over from placebo to pertuzumab. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks.

    Time frame: Placebo arm: Baseline to last dose of study treatment +42 days (or crossover date); Pertuzumab arm: Baseline to last dose of study treatment +42 days; Crossover arm: Crossover date to last dose of study treatment +42 days (see Description - time per arm)

  11. Overall Number of Participants Who Experienced at Least One Adverse Event That Resulted in Interruption or Modification of Any Study Medication

    Pertuzumab, trastuzumab, and docetaxel administration could have been delayed to assess or treat adverse events (AEs). Docetaxel dose reduction was allowed for myelosuppression, hepatic dysfunction, and other toxicities. No dose reduction was allowed for pertuzumab or trastuzumab. Multiple occurrences of the same adverse event in one participant was counted only once. AEs reported prior to first crossover treatment were included in the Placebo arm, and after that date in the Crossover arm, for participants who crossed over from placebo to pertuzumab. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks

    Time frame: Placebo arm: Baseline to last dose of study treatment +42 days (or crossover date); Pertuzumab arm: Baseline to last dose of study treatment +42 days; Crossover arm: Crossover date to last dose of study treatment +42 days (see Description - time per arm)

  12. Number of Participants Who Experienced at Least One Adverse Event During the Post-Treatment Follow-Up Period

    The post-treatment period was defined as the period following the treatment discontinuation visit. Only the following new adverse events (AEs) should have been reported during the post-treatment follow-up period: 1. Cardiac events (regardless of causality or seriousness) that started up to 1 year after the last dose, except for symptomatic left ventricular systolic dysfunction (regardless of causality) that started up to 3 years after the last dose; and 2. Treatment-related serious AEs, regardless of start date. AEs are listed by Medical Dictionary for Regulatory Activities, Version 21.1 (MedDRA v21.1) System Organ Class (SOC) and Preferred Term (PT); PTs fall under the SOC that is listed immediately above it in the table. Multiple occurrences of the same AE in one participant was counted only once. AEs reported prior to first crossover treatment were included in the Placebo arm, and after that date in the Crossover arm, for participants who crossed over from placebo to pertuzumab.

    Time frame: From Day 43 after discontinuation of all study medication to end of post-treatment follow-up period (up to 3 years)

  13. Number of Participants by Categories for the Maximum Absolute Decrease From Baseline in LVEF Value During the Treatment Period

    All participants were required to have an left ventricular ejection fraction (LVEF) ≥50% at baseline, as measured by echocardiogram (preferred) or multiple-gated acquisition (MUGA) scan. The same method of LVEF assessment and the same institution/facility used at baseline was used throughout the study, to the extent possible. The baseline value was defined as the last valid value recorded during the pre-treatment period before or on study Day 1. The maximum absolute decrease in LVEF value was defined as the lowest post-baseline value up to the end of the overall study treatment period. Data reported prior to first crossover treatment were included in the Placebo arm, and after that date in the Crossover arm, for participants who crossed over from placebo to pertuzumab. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks.

    Time frame: Every 9 weeks from the date of randomization until Treatment Discontinuation Visit (see Description for time on study treatment per arm)

  14. Baseline LVEF Value and Change in LVEF From Baseline at Maximum Absolute Decrease Value During the Treatment Period

    All participants were required to have a left ventricular ejection fraction (LVEF) ≥50% at baseline, as measured by echocardiogram (preferred) or multiple-gated acquisition (MUGA) scan. The same method of LVEF assessment and the same institution/facility used at baseline was used throughout the study, to the extent possible. The baseline value was defined as the last valid value recorded during the pre-treatment period before or on study Day 1. The maximum absolute decrease in LVEF value was defined as the lowest post-baseline value up to the end of the overall study treatment period. Only data reported prior to the date of first crossover treatment were included for participants who crossed over from placebo to pertuzumab.

    Time frame: Every 9 weeks from the date of randomization until Treatment Discontinuation Visit (median [range] time on study treatment per arm: Placebo: 49.3 [0.3-514.7] weeks; Pertuzumab: 75.7 [0.6-519.6] weeks)

  15. Number of Participants With Laboratory Abnormalities in Blood Biochemistry Tests by Highest Grade According to NCI-CTCAE v3.0 During the Treatment Period

    Clinical laboratory tests for blood biochemistry parameters were performed at local laboratories; any abnormal values (High or Low) were based on local laboratory normal ranges. Laboratory abnormalities are presented by the highest grade according to NCI-CTCAE v3.0. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks. ALP = alkaline phosphatase; GGT = gamma-glutamyl transferase; SGOT = serum glutamic-oxaloacetic transaminase; SGPT = serum glutamic-pyruvic transaminase

    Time frame: On Day 1 of every treatment cycle (1 cycle is 21 days) until Treatment Discontinuation Visit (see Description for time on study treatment per arm)

  16. Number of Participants With Laboratory Abnormalities in Hematology Tests by Highest Grade According to NCI-CTCAE v3.0 During the Treatment Period

    Clinical laboratory tests for hematology parameters were performed at local laboratories; any abnormal values (High or Low) were based on local laboratory normal ranges. Laboratory abnormalities are presented by the highest grade according to NCI-CTCAE v3.0. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks. INR = International Normalized Ratio; PTT = partial thromboplastin time; WBC = white blood cell

    Time frame: On Day 1 (and Day 8 for some measures) of every treatment cycle (1 cycle is 21 days) until Treatment Discontinuation Visit (see Description for time on study treatment per arm)

07

Results

Posted Sep 13, 2012

Participant flow

Participant flow — Overall Study
MilestonePertuzumab + Trastuzumab + DocetaxelPlacebo + Trastuzumab + Docetaxel
Started402406
Did not receive any study treatment22
Received at least one dose of pertuzumab3999
Received at least one dose of placebo1395
Crossover from placebo to pertuzumab050
Completed11973
Not completed283333
Withdrew: Death235280
Withdrew: Withdrew consent or lost to follow-up4853

Outcome measures

PrimaryProgression-Free Survival (PFS) Determined by an Independent Review Facility

PFS was defined as the time from randomization to first documented radiographical progressive disease (PD), as determined by an independent review facility (IRF) using RECIST version 1.0, or death from any cause (within 18 weeks of last tumor assessment), whichever occurred first (Kaplan-Meier method). For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum of the LD recorded since treatment started or the appearance of ≥1 new lesion. For non-target lesions, PD was defined as the appearance of ≥1 new lesion or unequivocal progression of existing lesions. Participants without IRF-determined PD or who had not died within 18 weeks of their last IRF-determined, progression-free tumor assessment were censored at the date of the last IRF-reviewed, evaluable tumor assessment; those with no post-baseline tumor assessment and who had not died within 18 weeks of baseline were censored at 1 day.

Time frame:
Tumor assessments every 9 weeks from randomization to IRF-determined PD or death from any cause, whichever occurred first, up to the primary completion date (up to 3 years, 3 months)
Reported as:
Median · Months
Progression-Free Survival (PFS) Determined by an Independent Review Facility
MonthsPertuzumab + Trastuzumab + DocetaxelPlacebo + Trastuzumab + Docetaxel
Progression-Free Survival (PFS) Determined by an Independent Review Facility18.5 (15 to 23)12.4 (10 to 13)
Statistical analysis
  • Pertuzumab + Trastuzumab + Docetaxel vs Placebo + Trastuzumab + Docetaxel · Log Rank (stratified) · p = <0.0001 (Tested at two-sided 5% significance level) · Cox proportional hazard: 0.62 · 95% CI 0.51 to 0.75Hazard ratio is comparing Pertuzumab arm with Placebo arm.
  • Pertuzumab + Trastuzumab + Docetaxel vs Placebo + Trastuzumab + Docetaxel · Log Rank (unstratified) · p = <0.0001 (Tested at two-sided 5% significance level) · Cox proportional hazard: 0.63 · 95% CI 0.52 to 0.76Hazard ratio is comparing Pertuzumab arm with Placebo arm.
SecondaryOverall Survival

Overall survival (OS) was the time from randomization to death from any cause, using Kaplan-Meier methodology. Survival data was collected every 18 weeks during the post-treatment follow-up period until death, loss to follow-up, or withdrawal of consent. Those who were alive, lost to follow up, or withdrew consent were censored at the latest date they participated in the study; those without post-baseline data were censored at 1 day. OS analyses were planned to take place at the primary completion date (First Interim), after 385 deaths (Event-Driven Final), and at the end of study (End-of-Study). A second interim OS analysis was planned due to a formal request from the European Medicines Agency. Median \[range\] time in weeks on study at each OS analysis (Pertuzumab vs. Placebo): First: 77.1 \[0.7-165.3\] vs. 73.1 \[0.4-165.3\]; Second: 117.1 \[0.7-207.9\] vs. 105.9 \[0.4-207.9\]; Event-Driven Final: 189.9 \[0.7-304.1\] vs. 140.5 \[0.4-301.6\]; End-of-Study: 201.8 \[0.7-520.0\] vs. 138.0 \[0.4-514.7\].

Time frame:
From randomization to death from any cause, up to each respective analysis data cut-off date (see the Description field for the median time on study per treatment arm)
Reported as:
Median · Months
Overall Survival
MonthsPertuzumab + Trastuzumab + DocetaxelPlacebo + Trastuzumab + Docetaxel
End-of-Study OS Analysis57.1 (50 to 72)40.8 (36 to 48)
Event-Driven Final OS Analysis56.5 (49 to NA)40.8 (36 to 48)
Second Interim OS AnalysisNA (42 to NA)37.6 (34 to NA)
First Interim OS AnalysisNA (NA to NA)NA (30 to NA)
Statistical analysis
  • Pertuzumab + Trastuzumab + Docetaxel vs Placebo + Trastuzumab + Docetaxel · Log Rank (stratified) · p = <0.0001 (Exploratory) · Cox proportional hazard: 0.69 · 95% CI 0.58 to 0.82Hazard ratio is comparing Pertuzumab arm with Placebo arm.
  • Pertuzumab + Trastuzumab + Docetaxel vs Placebo + Trastuzumab + Docetaxel · Log Rank (stratified) · p = 0.0002 (Exploratory) · Cox proportional hazard: 0.68 · 95% CI 0.56 to 0.84Hazard ratio is comparing Pertuzumab arm with Placebo arm.
  • Pertuzumab + Trastuzumab + Docetaxel vs Placebo + Trastuzumab + Docetaxel · Log Rank (stratified) · p = 0.0008 (The threshold for statistical significance was HR≤0.739, p≤0.0138.) · Cox proportional hazard: 0.66 · 95% CI 0.52 to 0.84Hazard ratio (HR) is comparing Pertuzumab arm with Placebo arm.
  • Pertuzumab + Trastuzumab + Docetaxel vs Placebo + Trastuzumab + Docetaxel · Log Rank (stratified) · p = 0.0050 (The threshold for statistical significance was HR≤0.603, p≤0.0012.) · Cox proportional hazard: 0.64 · 95% CI 0.47 to 0.88Hazard ratio (HR) is comparing pertuzumab with placebo arms.
SecondaryProgression-Free Survival (PFS) Determined by the Investigator

PFS was defined as the time from randomization to first documented radiographical progressive disease (PD), as determined by the investigator using RECIST version 1.0, or death from any cause (within 18 weeks of last tumor assessment), whichever occurred first (Kaplan-Meier method). For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum of the LD recorded since treatment started or the appearance of ≥1 new lesion. For non-target lesions, PD was defined as the appearance of ≥1 new lesion or unequivocal progression of existing lesions. Participants without PD or who had not died within 18 weeks of their last investigator-determined, progression-free tumor assessment were censored at the date of the last investigator tumor assessment; those with no post-baseline tumor assessment and who had not died within 18 weeks of baseline were censored at 1 day.

Time frame:
Tumor assessments every 9 weeks from randomization to investigator-determined PD or death from any cause, whichever occurred first (median [range] time on study in pertuzumab vs. placebo arms: 201.8 [0.7-520.0] weeks vs. 138.0 [0.4-514.7] weeks)
Reported as:
Median · Months
Progression-Free Survival (PFS) Determined by the Investigator
MonthsPertuzumab + Trastuzumab + DocetaxelPlacebo + Trastuzumab + Docetaxel
Progression-Free Survival (PFS) Determined by the Investigator18.7 (17 to 22)12.4 (10 to 14)
Statistical analysis
  • Pertuzumab + Trastuzumab + Docetaxel vs Placebo + Trastuzumab + Docetaxel · Log Rank (stratified) · p = <0.0001 · Cox proportional hazard: 0.69 · 95% CI 0.59 to 0.81Hazard ratio is comparing Pertuzumab arm with Placebo arm.
SecondaryObjective Response Determined by an Independent Review Facility

An objective response was defined as the percentage of participants with confirmed best overall response of complete response (CR) or partial response (PR) determined by an independent review facility (IRF) using RECIST v1.0 on two consecutive occasions ≥4 weeks apart. For target lesions, CR: disappearance of all target lesions; PR: ≥30% decrease in the sum of the longest diameter (LD) of target lesions (baseline sum LD as reference); PD: ≥20% increase in the sum of the LD of target lesions (smallest sum of the LD recorded as reference) or appearance of ≥1 new lesion; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase for PD. For non-target lesions, CR: disappearance of all non-target lesions; Incomplete/SD: persistence of ≥1 non-target lesions; PD: unequivocal progression of existing non-target lesions. 95% confidence intervals (CI) were calculated only for clinical responses using the Pearson-Clopper method.

Time frame:
Tumor assessments every 9 weeks from Baseline until IRF-determined progressive disease (PD), death, or first administration of next line of anti-cancer therapy (whichever occurred first), up to the primary completion date (up to 3 years, 3 months)
Reported as:
Number · Percentage of patients
Objective Response Determined by an Independent Review Facility
Percentage of patientsPertuzumab + Trastuzumab + DocetaxelPlacebo + Trastuzumab + Docetaxel
Objective Response (CR + PR)80.2 (75.6 to 84.3)69.3 (64.1 to 74.2)
Complete Response (CR)5.5 (3.4 to 8.5)4.2 (2.3 to 6.9)
Partial Response (PR)74.6 (69.7 to 79.2)65.2 (59.8 to 70.3)
Stable Disease (SD)14.6 (11.0 to 18.8)20.8 (16.6 to 25.6)
Progressive Disease (PD)3.8 (2.0 to 6.4)8.3 (5.6 to 11.8)
Unable to Assess (UA)0.6 (0.1 to 2.1)0.6 (0.1 to 2.1)
Missing (No Assessment)0.9 (NA to NA)0.9 (NA to NA)
Statistical analysis
  • Pertuzumab + Trastuzumab + Docetaxel vs Placebo + Trastuzumab + Docetaxel · Mantel Haenszel · p = 0.0011 · Difference in objective response rates: 10.83 · 95% CI 4.2 to 17.5Difference in the objective response rates between arms is calculated as Pertuzumab arm minus Placebo arm. The 95% CI was calculated using the Hauck-Anderson method.
  • Pertuzumab + Trastuzumab + Docetaxel vs Placebo + Trastuzumab + Docetaxel · Odds ratio (or): 1.79 · 95% CI 1.26 to 2.54
SecondaryDuration of Objective Response Determined by an Independent Review Facility

Duration of objective response (estimated using the Kaplan-Meier method) was defined as the time from the initial confirmed complete response (CR) or partial response (PR), the date of tumor assessment at which the CR/PR was first detected by the independent review facility (IRF) using RECIST version 1.0, until the date of IRF-determined progressive disease (PD), death from any cause within 18 weeks of the last tumor assessment, or first administration of next line of anti-cancer therapy (whichever occurred first). If the visit when the initial CR or PR was observed spanned multiple dates, the latest date was used. Only participants in the ITT analysis population with an IRF-determined objective response (CR or PR), observed prior to IRF-assessed PD, death or next line of anti-cancer therapy, were included in the analysis. Participants who did not progress or die after they had a confirmed response were censored at the date of their last IRF-evaluable tumor measurement.

Time frame:
From initial IRF-confirmed objective response until IRF-determined progressive disease (PD), death, or first administration of next line of anti-cancer therapy (whichever occurred first), up to the primary completion date (up to 3 years, 3 months)
Reported as:
Median · Weeks
Duration of Objective Response Determined by an Independent Review Facility
WeeksPertuzumab + Trastuzumab + DocetaxelPlacebo + Trastuzumab + Docetaxel
Duration of Objective Response Determined by an Independent Review Facility87.6 (71 to 106)54.1 (46 to 64)
Statistical analysis
  • Pertuzumab + Trastuzumab + Docetaxel vs Placebo + Trastuzumab + Docetaxel · Cox proportional hazard: 0.66 · 95% CI 0.51 to 0.85
SecondaryTime to Symptom Progression

Time to symptom progression was defined as the time from randomization to the first symptom progression as measured by the Functional Assessment of Cancer Therapy-for patients with Breast Cancer (FACT-B) questionnaire with the Trial Outcomes Index-Physical/Functional/Breast (TOI-PFB) subscale. The FACT-B TOI-PFB subscale contains 24 items from 3 subsections of the FACT-B questionnaire: Physical well-being, functional well-being, and additional concerns for breast cancer patients (breast cancer subscale \[BCS\]). All items in the questionnaire were rated by the patient on a 5-point scale ranging from 0 ("not at all") to 4 ("very much"). The total score ranged from 0 to 96. A higher score indicates better perceived quality of life. A positive change score from baseline indicates improvement. Symptom progression was defined as a decrease from baseline of 5 points or more.

Time frame:
Every 9 weeks from Baseline until investigator-determined progressive disease, up to the primary completion date (up to 3 years, 3 months)
Reported as:
Median · Weeks
Time to Symptom Progression
WeeksPertuzumab + Trastuzumab + DocetaxelPlacebo + Trastuzumab + Docetaxel
Time to Symptom Progression18.4 (18 to 27)18.3 (18 to 27)
Statistical analysis
  • Pertuzumab + Trastuzumab + Docetaxel vs Placebo + Trastuzumab + Docetaxel · Log Rank (stratified) · p = 0.7161 (Stratified by prior treatment status and region.) · Cox proportional hazard: 0.97 · 95% CI 0.81 to 1.16Hazard ratio is comparing Pertuzumab arm with Placebo arm.
SecondaryOverall Number of Participants Who Experienced at Least One Adverse Event, Including Serious and Non-Serious Adverse Events, by Most Severe Intensity (According to NCI-CTCAE v3.0) During the Treatment Period

Adverse event (AE) severity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0 (NCI-CTCAE v3.0); if the AE was not specifically listed, the following grades of severity were used: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening or disabling; and Grade 5 = death. Severe and serious are not synonymous. Severity refers to the intensity of an AE, whereas a serious AE must meet criteria set out in the protocol; both were independently assessed for each AE. Only the most severe intensity was counted for multiple occurrences of the same AE in one participant. AEs reported prior to first crossover treatment were included in the Placebo arm, and in the Crossover arm after that date, for participants who crossed over from placebo to pertuzumab. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks.

Time frame:
Placebo arm: Baseline to last dose of study treatment +42 days (or crossover date); Pertuzumab arm: Baseline to last dose of study treatment +42 days; Crossover arm: Crossover date to last dose of study treatment +42 days (see Description - time per arm)
Reported as:
Count of participants · Participants
Overall Number of Participants Who Experienced at Least One Adverse Event, Including Serious and Non-Serious Adverse Events, by Most Severe Intensity (According to NCI-CTCAE v3.0) During the Treatment Period
ParticipantsPlacebo + Trastuzumab + DocetaxelPertuzumab + Trastuzumab + DocetaxelCrossover From Placebo to Pertuzumab
At Least One Serious AE - All Grades11616010
At Least One Non-Serious AE - All Grades38640045
At Least One AE - All Grades39140847
At Least One AE - Grade 136838644
At Least One AE - Grade 235038334
At Least One AE - Grade 322926411
At Least One AE - Grade 41581671
At Least One AE - Grade 51281
SecondaryOverall Number of Adverse Events by Severity (NCI-CTCAE v3.0 All Grades and Grades 3 to 5) Per 100 Patient-Years of Exposure During the Treatment Period

Adverse event (AE) severity, including serious and non-serious AEs, was assessed according to the NCI-CTCAE version 3.0; if the AE was not specifically listed, the following grades of severity were used: Grade 1 is mild; Grade 2 is moderate; Grade 3 is severe; Grade 4 is life-threatening or disabling; and Grade 5 is death. Multiple occurrences of the same AE in 1 participant were counted multiple times. Only AEs that started during the overall study treatment period were included. The cutoff date for inclusion of events and for calculation of patient-years was the date of the most recent follow-up of the participant, defined as the last available date during the treatment period, excluding pre-treatment and safety follow-up data. Confidence intervals were calculated assuming the number of events followed a Poisson distribution. Data reported prior to the date of first crossover treatment were included under the Placebo arm for participants who crossed over from placebo to pertuzumab.

Time frame:
From Baseline to 42 days after the last dose of study treatment (total patient-years of exposure on study treatment in Placebo vs. Pertuzumab arms: 526.81 vs. 989.88 patient-years)
Reported as:
Number · Events per 100 patient-years
Overall Number of Adverse Events by Severity (NCI-CTCAE v3.0 All Grades and Grades 3 to 5) Per 100 Patient-Years of Exposure During the Treatment Period
Events per 100 patient-yearsPlacebo + Trastuzumab + DocetaxelPertuzumab + Trastuzumab + Docetaxel
All Grades1720.2 (1690.6 to 1750.2)1203.0 (1184.9 to 1221.3)
Grades 3 to 5225.3 (214.7 to 236.4)131.7 (125.8 to 137.9)
SecondaryCardiac-Related AEs to Monitor: Number of Participants Who Experienced at Least One Symptomatic Left Ventricular Dysfunction (LVD), Any LVD, or Serious AE Suggestive of Congestive Heart Failure by Severity During the Treatment Period

Cardiac-related adverse events (AEs) to monitor during the study included investigator-assessed symptomatic left ventricular dysfunction (LVD), any LVD, or a serious adverse event (SAE) suggestive of congestive heart failure (CHF). All cardiac-related AEs were graded for severity according to NCI-CTCAE v3.0. Asymptomatic (Grades 1-2) and symptomatic (Grades 3-5) left ventricular systolic dysfunction (LVSD) both coded to the MedDRA preferred term LVD. Investigator-assessed events of symptomatic LVD were also graded for severity of symptoms according to Classes I (least severe) to IV (most severe) of the New York Heart Association (NYHA) Classification. SAEs suggestive of CHF were identified as serious events from the Standardized MedDRA Query (SMQ) (Wide) 'Cardiac Failure'. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks.

Time frame:
Placebo arm: Baseline to last dose of study treatment +42 days (or crossover date); Pertuzumab arm: Baseline to last dose of study treatment +42 days; Crossover arm: Crossover date to last dose of study treatment +42 days (see Description - time per arm)
Reported as:
Count of participants · Participants
Cardiac-Related AEs to Monitor: Number of Participants Who Experienced at Least One Symptomatic Left Ventricular Dysfunction (LVD), Any LVD, or Serious AE Suggestive of Congestive Heart Failure by Severity During the Treatment Period
ParticipantsPlacebo + Trastuzumab + DocetaxelPertuzumab + Trastuzumab + DocetaxelCrossover From Placebo to Pertuzumab
Symptomatic LVD(Investigator)-All NYHA Classes761
Symptomatic LVD(Investigator)-NYHA Classes III/IV441
Any LVD - All NCI-CTCAE Grades34323
Any LVD - NCI-CTCAE Grade ≥31362
SAE Suggestive of CHF - All NCI-CTCAE Grades881
SAE Suggestive of CHF - NCI-CTCAE Grade ≥3771
SecondaryNumber of Participants Who Experienced at Least One Adverse Event to Monitor (Excluding Cardiac-Related AEs) by Severity During the Treatment Period

The clinical diagnoses listed in this table, excluding cardiac safety (summarized separately), were also selected as adverse events (AEs) to monitor based on clinical and nonclinical data for pertuzumab and the safety profile established for trastuzumab, monoclonal antibodies in general, and potential effects associated with HER receptor inhibition. Search strategies were defined by single or aggregate MedDRA Preferred Terms (PT) through Standardized MedDRA Queries (SMQ), where possible, or based on Roche AE Group Terms (AEGT). Diarrhoea AEs: High-Level Term (HLT) 'Diarrhoea (excl. infective)' and PT 'Diarrhoea infectious'. Leukopenic and Febrile Neutropenic Infections: AEs from 'Infections \& Infestations' with start ≤14 days after start date of Grade ≥3 AEs in SMQ(narrow) 'Leukopenia' or PT 'Febrile neutropenia', respectively. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks.

Time frame:
Placebo arm: Baseline to last dose of study treatment +42 days (or crossover date); Pertuzumab arm: Baseline to last dose of study treatment +42 days; Crossover arm: Crossover date to last dose of study treatment +42 days (see Description - time per arm)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced at Least One Adverse Event to Monitor (Excluding Cardiac-Related AEs) by Severity During the Treatment Period
ParticipantsPlacebo + Trastuzumab + DocetaxelPertuzumab + Trastuzumab + DocetaxelCrossover From Placebo to Pertuzumab
Diarrhoea (HLT+PT) - All Grades19128025
Diarrhoea (HLT+PT) - Grade ≥320401
Rash (AEGT) - All Grades15521318
Rash (AEGT) - Grade ≥36150
Leukopenia (SMQ-narrow) - All Grades2312571
Leukopenia (SMQ-narrow) - Grade ≥32112380
Leukopenic Infection (PTs) - All Grades38530
Leukopenic Infection (PTs) - Grade ≥39180
Febrile Neutropenic Infection (PTs) - All Grades3140
Febrile Neutropenic Infection (PTs) - Grade ≥3160
Anaphylaxis and Hypersensitivity (AEGT)-All Grades37481
Anaphylaxis and Hypersensitivity (AEGT)-Grade ≥31090
Interstitial Lung Disease (SMQ-narrow) -All Grades6101
Interstitial Lung Disease (SMQ-narrow) -Grade ≥3230
QT Prolongation (SMQ-wide) - All Grades5160
QT Prolongation (SMQ-wide) - Grade ≥3170
Mucositis (AEGT) - All Grades15420812
Mucositis (AEGT) - Grade ≥38140
Drug-Related Hepatic Disorder(SMQ-wide)-All Grades43470
Drug-Related Hepatic Disorder (SMQ-wide)-Grade ≥3580
SecondaryOverall Number of Participants Who Experienced at Least One Adverse Event Leading to Discontinuation of Any or All Study Medication

Participants could continue study treatment with pertuzumab/placebo plus trastuzumab when docetaxel was discontinued due to an adverse event (AE). Discontinuation of pertuzumab/placebo or trastuzumab due to an AE led to discontinuation of all study medication. The number of participants who discontinued any study medication due to an AE includes those who discontinued all study medication and those who discontinued docetaxel only and then continued on targeted therapy (note: some of these participants may have subsequently discontinued all treatment due to a separate AE). Multiple occurrences of the same adverse event in 1 participant was counted only once. AEs reported prior to first crossover treatment were included in the Placebo arm, and after that date in the Crossover arm, for those who crossed over from placebo to pertuzumab. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks.

Time frame:
Placebo arm: Baseline to last dose of study treatment +42 days (or crossover date); Pertuzumab arm: Baseline to last dose of study treatment +42 days; Crossover arm: Crossover date to last dose of study treatment +42 days (see Description - time per arm)
Reported as:
Count of participants · Participants
Overall Number of Participants Who Experienced at Least One Adverse Event Leading to Discontinuation of Any or All Study Medication
ParticipantsPlacebo + Trastuzumab + DocetaxelPertuzumab + Trastuzumab + DocetaxelCrossover From Placebo to Pertuzumab
AE Leading to Discontinuation-Any Study Medication1141315
AE Leading to Discontinuation-All Study Medication24394
SecondaryOverall Number of Participants Who Experienced at Least One Adverse Event That Resulted in Interruption or Modification of Any Study Medication

Pertuzumab, trastuzumab, and docetaxel administration could have been delayed to assess or treat adverse events (AEs). Docetaxel dose reduction was allowed for myelosuppression, hepatic dysfunction, and other toxicities. No dose reduction was allowed for pertuzumab or trastuzumab. Multiple occurrences of the same adverse event in one participant was counted only once. AEs reported prior to first crossover treatment were included in the Placebo arm, and after that date in the Crossover arm, for participants who crossed over from placebo to pertuzumab. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks

Time frame:
Placebo arm: Baseline to last dose of study treatment +42 days (or crossover date); Pertuzumab arm: Baseline to last dose of study treatment +42 days; Crossover arm: Crossover date to last dose of study treatment +42 days (see Description - time per arm)
Reported as:
Count of participants · Participants
Overall Number of Participants Who Experienced at Least One Adverse Event That Resulted in Interruption or Modification of Any Study Medication
ParticipantsPlacebo + Trastuzumab + DocetaxelPertuzumab + Trastuzumab + DocetaxelCrossover From Placebo to Pertuzumab
Overall Number of Participants Who Experienced at Least One Adverse Event That Resulted in Interruption or Modification of Any Study Medication21726516
SecondaryNumber of Participants Who Experienced at Least One Adverse Event During the Post-Treatment Follow-Up Period

The post-treatment period was defined as the period following the treatment discontinuation visit. Only the following new adverse events (AEs) should have been reported during the post-treatment follow-up period: 1. Cardiac events (regardless of causality or seriousness) that started up to 1 year after the last dose, except for symptomatic left ventricular systolic dysfunction (regardless of causality) that started up to 3 years after the last dose; and 2. Treatment-related serious AEs, regardless of start date. AEs are listed by Medical Dictionary for Regulatory Activities, Version 21.1 (MedDRA v21.1) System Organ Class (SOC) and Preferred Term (PT); PTs fall under the SOC that is listed immediately above it in the table. Multiple occurrences of the same AE in one participant was counted only once. AEs reported prior to first crossover treatment were included in the Placebo arm, and after that date in the Crossover arm, for participants who crossed over from placebo to pertuzumab.

Time frame:
From Day 43 after discontinuation of all study medication to end of post-treatment follow-up period (up to 3 years)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced at Least One Adverse Event During the Post-Treatment Follow-Up Period
ParticipantsPlacebo + Trastuzumab + DocetaxelPertuzumab + Trastuzumab + DocetaxelCrossover From Placebo to Pertuzumab
Total with at Least One AE During Post-Treatment18173
Cardiac Disorders (SOC)891
Left Ventricular Dysfunction (PT)651
Cardiac Failure (PT)020
Bundle Branch Block Left (PT)010
Cardiopulmonary Failure (PT)100
Myocardial Ischaemia (PT)100
Pericardial Effusion (PT)010
Prinzmetal Angina (PT)100
General Disorders & Admin. Site Conditions (SOC)320
Oedema Peripheral (PT)210
Asthenia (PT)100
Influenza Like Illness (PT)010
Infections & Infestations (SOC)002
Influenza (PT)001
Viral Infection (PT)001
Abscess Limb (PT)010
Nasopharyngitis (PT)100
Subcutaneous Abscess (PT)010
Musculoskeletal & Connective Tissue Disorders(SOC)001
Back Pain (PT)001
Pain in Extremity (PT)100
Nervous System Disorders (SOC)220
Neuropathy Peripheral (PT)110
Cognitive Disorder (PT)100
Dizziness (PT)010
Headache (PT)010
Respiratory, Thoracic & Mediastinal Disorders(SOC)210
Cough (PT)100
Dyspnoea (PT)100
Rhinitis Allergic (PT)010
Skin & Subcutaneous Tissue Disorders (SOC)120
Erythema (PT)010
Nail Disorder (PT)100
Rash Macular (PT)010
Blood & Lymphatic System Disorders (SOC)110
Febrile Neutropenia (PT)100
Leukopenia (PT)010
Gastrointestinal Disorders (SOC)020
Diarrhoea (PT)010
Stomatitis (PT)010
Endocrine Disorders (SOC)100
Thyroid Mass (PT)100
Eye Disorders (SOC)100
Retinal Detachment (PT)100
Immune System Disorders (SOC)010
Iodine Allergy (PT)010
Investigations (SOC)100
Aspartate Aminotransferase Increased (PT)100
Renal & Urinary Disorders (SOC)010
Dysuria (PT)010
Reproductive System & Breast Disorders (SOC)010
Breast Induration (PT)010
Vascular Disorders (SOC)010
Venous Thrombosis (PT)010
SecondaryNumber of Participants by Categories for the Maximum Absolute Decrease From Baseline in LVEF Value During the Treatment Period

All participants were required to have an left ventricular ejection fraction (LVEF) ≥50% at baseline, as measured by echocardiogram (preferred) or multiple-gated acquisition (MUGA) scan. The same method of LVEF assessment and the same institution/facility used at baseline was used throughout the study, to the extent possible. The baseline value was defined as the last valid value recorded during the pre-treatment period before or on study Day 1. The maximum absolute decrease in LVEF value was defined as the lowest post-baseline value up to the end of the overall study treatment period. Data reported prior to first crossover treatment were included in the Placebo arm, and after that date in the Crossover arm, for participants who crossed over from placebo to pertuzumab. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks.

Time frame:
Every 9 weeks from the date of randomization until Treatment Discontinuation Visit (see Description for time on study treatment per arm)
Reported as:
Count of participants · Participants
Number of Participants by Categories for the Maximum Absolute Decrease From Baseline in LVEF Value During the Treatment Period
ParticipantsPlacebo + Trastuzumab + DocetaxelPertuzumab + Trastuzumab + DocetaxelCrossover From Placebo to Pertuzumab
LVEF Increase/No Change/Decrease FromBL <10%Points25224930
LVEF <50% and Decrease From BL ≥10% to <15% Points970
LVEF <50% and Decrease From BL ≥15% Points19213
LVEF ≥50% and Decrease From BL ≥10% Points9511515
No Baseline (BL) LVEF Value321
SecondaryBaseline LVEF Value and Change in LVEF From Baseline at Maximum Absolute Decrease Value During the Treatment Period

All participants were required to have a left ventricular ejection fraction (LVEF) ≥50% at baseline, as measured by echocardiogram (preferred) or multiple-gated acquisition (MUGA) scan. The same method of LVEF assessment and the same institution/facility used at baseline was used throughout the study, to the extent possible. The baseline value was defined as the last valid value recorded during the pre-treatment period before or on study Day 1. The maximum absolute decrease in LVEF value was defined as the lowest post-baseline value up to the end of the overall study treatment period. Only data reported prior to the date of first crossover treatment were included for participants who crossed over from placebo to pertuzumab.

Time frame:
Every 9 weeks from the date of randomization until Treatment Discontinuation Visit (median [range] time on study treatment per arm: Placebo: 49.3 [0.3-514.7] weeks; Pertuzumab: 75.7 [0.6-519.6] weeks)
Reported as:
Mean · Percentage points of LVEF
Baseline LVEF Value and Change in LVEF From Baseline at Maximum Absolute Decrease Value During the Treatment Period
Percentage points of LVEFPlacebo + Trastuzumab + DocetaxelPertuzumab + Trastuzumab + Docetaxel
Baseline (BL) LVEF Value65.6 ± 6.5164.8 ± 6.71
Change in LVEF From BL at Maximum Decrease Value-7.3 ± 7.15-7.5 ± 7.75
Statistical analysis
  • Placebo + Trastuzumab + Docetaxel vs Pertuzumab + Trastuzumab + Docetaxel · Wilcoxon Rank Sum Test · p = 0.7174
SecondaryNumber of Participants With Laboratory Abnormalities in Blood Biochemistry Tests by Highest Grade According to NCI-CTCAE v3.0 During the Treatment Period

Clinical laboratory tests for blood biochemistry parameters were performed at local laboratories; any abnormal values (High or Low) were based on local laboratory normal ranges. Laboratory abnormalities are presented by the highest grade according to NCI-CTCAE v3.0. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks. ALP = alkaline phosphatase; GGT = gamma-glutamyl transferase; SGOT = serum glutamic-oxaloacetic transaminase; SGPT = serum glutamic-pyruvic transaminase

Time frame:
On Day 1 of every treatment cycle (1 cycle is 21 days) until Treatment Discontinuation Visit (see Description for time on study treatment per arm)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities in Blood Biochemistry Tests by Highest Grade According to NCI-CTCAE v3.0 During the Treatment Period
ParticipantsPlacebo + Trastuzumab + DocetaxelPertuzumab + Trastuzumab + DocetaxelCrossover From Placebo to Pertuzumab
Albumin (g/L) - Low, Any Grade (Gr.)16319615
Albumin (g/L) - Low, Gr. 111313210
Albumin (g/L) - Low, Gr. 246584
Albumin (g/L) - Low, Gr. 3461
Albumin (g/L) - Low, Gr. 4000
ALP (U/L) - High, Any Gr.18421017
ALP (U/L) - High, Gr. 115817717
ALP (U/L) - High, Gr. 219240
ALP (U/L) - High, Gr. 3790
ALP (U/L) - High, Gr. 4000
Calcium (mmol/L) - Low, Any Gr.15620314
Calcium (mmol/L) - Low, Gr. 110713911
Calcium (mmol/L) - Low, Gr. 245490
Calcium (mmol/L) - Low, Gr. 3371
Calcium (mmol/L) - Low, Gr. 4182
Calcium (mmol/L) - High, Any Gr.547912
Calcium (mmol/L) - High, Gr. 150657
Calcium (mmol/L) - High, Gr. 2021
Calcium (mmol/L) - High, Gr. 3320
Calcium (mmol/L) - High, Gr. 41104
Creatinine (umol/L) - High, Any Gr.31734638
Creatinine (umol/L) - High, Gr. 127127927
Creatinine (umol/L) - High, Gr. 244549
Creatinine (umol/L) - High, Gr. 3260
Creatinine (umol/L) - High, Gr. 4072
Fasting Glucose (mmol/L) - Low, Any Gr.42756
Fasting Glucose (mmol/L) - Low, Gr. 132614
Fasting Glucose (mmol/L) - Low, Gr. 2990
Fasting Glucose (mmol/L) - Low, Gr. 3120
Fasting Glucose (mmol/L) - Low, Gr. 4032
Fasting Glucose (mmol/L) - High, Any Gr.27129934
Fasting Glucose (mmol/L) - High, Gr. 116819226
Fasting Glucose (mmol/L) - High, Gr. 283788
Fasting Glucose (mmol/L) - High, Gr. 320260
Fasting Glucose (mmol/L) - High, Gr. 4030
GGT (U/L) - High, Any Gr.20922514
GGT (U/L) - High, Gr. 11331449
GGT (U/L) - High, Gr. 241524
GGT (U/L) - High, Gr. 330271
GGT (U/L) - High, Gr. 4520
Magnesium (mmol/L) - Low, Any Gr.791178
Magnesium (mmol/L) - Low, Gr. 171986
Magnesium (mmol/L) - Low, Gr. 27130
Magnesium (mmol/L) - Low, Gr. 3130
Magnesium (mmol/L) - Low, Gr. 4032
Magnesium (mmol/L) - High, Any Gr.7610516
Magnesium (mmol/L) - High, Gr. 1588011
Magnesium (mmol/L) - High, Gr. 2000
Magnesium (mmol/L) - High, Gr. 318224
Magnesium (mmol/L) - High, Gr. 4031
Potassium (mmol/L) - Low, Any Gr.8014411
Potassium (mmol/L) - Low, Gr. 1000
Potassium (mmol/L) - Low, Gr. 2681188
Potassium (mmol/L) - Low, Gr. 310182
Potassium (mmol/L) - Low, Gr. 4281
Potassium (mmol/L) - High, Any Gr.677813
Potassium (mmol/L) - High, Gr. 1495511
Potassium (mmol/L) - High, Gr. 215172
Potassium (mmol/L) - High, Gr. 3360
Potassium (mmol/L) - High, Gr. 4000
SGOT (U/L) - High, Any Gr.18419317
SGOT (U/L) - High, Gr. 116917015
SGOT (U/L) - High, Gr. 211122
SGOT (U/L) - High, Gr. 34100
SGOT (U/L) - High, Gr. 4010
SGPT (U/L) - High, Any Gr.19520919
SGPT (U/L) - High, Gr. 117217517
SGPT (U/L) - High, Gr. 218192
SGPT (U/L) - High, Gr. 35140
SGPT (U/L) - High, Gr. 4010
Sodium (mmol/L) - Low, Any Gr.10913525
Sodium (mmol/L) - Low, Gr. 18712122
Sodium (mmol/L) - Low, Gr. 2000
Sodium (mmol/L) - Low, Gr. 321121
Sodium (mmol/L) - Low, Gr. 4122
Sodium (mmol/L) - High, Any Gr.761039
Sodium (mmol/L) - High, Gr. 171917
Sodium (mmol/L) - High, Gr. 2492
Sodium (mmol/L) - High, Gr. 3120
Sodium (mmol/L) - High, Gr. 4010
Total Bilirubin (umol/L) - High, Any Gr.35577
Total Bilirubin (umol/L) - High, Gr. 126446
Total Bilirubin (umol/L) - High, Gr. 2790
Total Bilirubin (umol/L) - High, Gr. 3220
Total Bilirubin (umol/L) - High, Gr. 4021
Uric Acid (umol/L) - High, Any Gr.11811315
Uric Acid (umol/L) - High, Gr. 1000
Uric Acid (umol/L) - High, Gr. 2000
Uric Acid (umol/L) - High, Gr. 31169810
Uric Acid (umol/L) - High, Gr. 42155
SecondaryNumber of Participants With Laboratory Abnormalities in Hematology Tests by Highest Grade According to NCI-CTCAE v3.0 During the Treatment Period

Clinical laboratory tests for hematology parameters were performed at local laboratories; any abnormal values (High or Low) were based on local laboratory normal ranges. Laboratory abnormalities are presented by the highest grade according to NCI-CTCAE v3.0. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks. INR = International Normalized Ratio; PTT = partial thromboplastin time; WBC = white blood cell

Time frame:
On Day 1 (and Day 8 for some measures) of every treatment cycle (1 cycle is 21 days) until Treatment Discontinuation Visit (see Description for time on study treatment per arm)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities in Hematology Tests by Highest Grade According to NCI-CTCAE v3.0 During the Treatment Period
ParticipantsPlacebo + Trastuzumab + DocetaxelPertuzumab + Trastuzumab + DocetaxelCrossover From Placebo to Pertuzumab
Hemoglobin (g/L) - Low, Any Grade (Gr.)35037220
Hemoglobin (g/L) - Low, Gr. 12021869
Hemoglobin (g/L) - Low, Gr. 21271616
Hemoglobin (g/L) - Low, Gr. 321255
Hemoglobin (g/L) - Low, Gr. 4000
Hemoglobin (g/L) - High, Any Gr.10234
Hemoglobin (g/L) - High, Gr. 19202
Hemoglobin (g/L) - High, Gr. 2120
Hemoglobin (g/L) - High, Gr. 3012
Hemoglobin (g/L) - High, Gr. 4000
Lymphocytes (10^9/L) - Low, Any Gr.2592768
Lymphocytes (10^9/L) - Low, Gr. 136390
Lymphocytes (10^9/L) - Low, Gr. 21281364
Lymphocytes (10^9/L) - Low, Gr. 364693
Lymphocytes (10^9/L) - Low, Gr. 431321
Lymphocytes (10^9/L)- High, Any Gr.58729
Lymphocytes (10^9/L)- High, Gr. 1000
Lymphocytes (10^9/L)- High, Gr. 249576
Lymphocytes (10^9/L)- High, Gr. 39153
Lymphocytes (10^9/L)- High, Gr. 4000
Neutrophils (10^9/L)- Low, Any Gr.3493712
Neutrophils (10^9/L)- Low, Gr. 1740
Neutrophils (10^9/L)- Low, Gr. 225340
Neutrophils (10^9/L)- Low, Gr. 381990
Neutrophils (10^9/L)- Low, Gr. 42362342
PTT (sec) - High, Any Gr.691
PTT (sec) - High, Gr. 1521
PTT (sec) - High, Gr. 2040
PTT (sec) - High, Gr. 3130
PTT (sec) - High, Gr. 4000
Platelets (10^9/L) - Low, Any Gr.829213
Platelets (10^9/L) - Low, Gr. 1757811
Platelets (10^9/L) - Low, Gr. 2550
Platelets (10^9/L) - Low, Gr. 3230
Platelets (10^9/L) - Low, Gr. 4062
Prothrombin Time (INR) - High, Any Gr.13515711
Prothrombin Time (INR) - High, Gr. 11271369
Prothrombin Time (INR) - High, Gr. 2360
Prothrombin Time (INR) - High, Gr. 35152
Prothrombin Time (INR) - High, Gr. 4000
WBC (10^9/L) - Low, Any Gr.3663875
WBC (10^9/L) - Low, Gr. 136341
WBC (10^9/L) - Low, Gr. 292923
WBC (10^9/L) - Low, Gr. 31862060
WBC (10^9/L) - Low, Gr. 452551
WBC (10^9/L) - High, Any Gr.031
WBC (10^9/L) - High, Gr. 1000
WBC (10^9/L) - High, Gr. 2000
WBC (10^9/L) - High, Gr. 3031
WBC (10^9/L) - High, Gr. 4000

Adverse events

Collected over From first treatment dose (12-Feb-2008) through to end of study (23-Nov-2018) for a total safety analysis timeframe of 10 years, 9.5 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo + Trastuzumab + Docetaxel261/396 (65.9%)116/396 (29.3%)386/396 (97.5%)
Pertuzumab + Trastuzumab + Docetaxel238/408 (58.3%)160/408 (39.2%)400/408 (98%)
Crossover From Placebo to Pertuzumab14/50 (28%)10/50 (20%)45/50 (90%)
Most frequent serious events
Showing 10 of 179
Most frequent serious events
EventPlacebo + Trastuzumab + DocetaxelPertuzumab + Trastuzumab + DocetaxelCrossover From Placebo to Pertuzumab
Febrile neutropeniaBlood and lymphatic system disorders20/39646/4080/50
NeutropeniaBlood and lymphatic system disorders19/39618/4080/50
PyrexiaGeneral disorders3/3966/4082/50
DiarrhoeaGastrointestinal disorders5/39613/4081/50
PneumoniaInfections and infestations11/3967/4081/50
CellulitisInfections and infestations2/39610/4080/50
AnaemiaBlood and lymphatic system disorders3/3963/4081/50
Left ventricular dysfunctionCardiac disorders7/3966/4081/50
CataractEye disorders0/3962/4081/50
DeathGeneral disorders0/3961/4081/50
Most frequent other events
Showing 10 of 79
Most frequent other events
EventPlacebo + Trastuzumab + DocetaxelPertuzumab + Trastuzumab + DocetaxelCrossover From Placebo to Pertuzumab
DiarrhoeaGastrointestinal disorders191/396277/40825/50
AlopeciaSkin and subcutaneous tissue disorders240/396248/4084/50
NeutropeniaBlood and lymphatic system disorders191/396209/4081/50
NauseaGastrointestinal disorders168/396184/4084/50
FatigueGeneral disorders148/396156/4085/50
RashSkin and subcutaneous tissue disorders96/396156/40811/50
AstheniaGeneral disorders122/396114/4083/50
Decreased appetiteMetabolism and nutrition disorders106/396120/4082/50
Oedema peripheralGeneral disorders111/396102/4081/50
Mucosal inflammationGeneral disorders78/396111/4081/50

Baseline characteristics

ITT population

Age, Continuous
Age, Continuous(years)Pertuzumab + Trastuzumab + DocetaxelPlacebo + Trastuzumab + DocetaxelTotal
Mean53.4 ± 10.9453.5 ± 11.3553.5 ± 11.14
Sex: Female, Male
Sex: Female, Male(Participants)Pertuzumab + Trastuzumab + DocetaxelPlacebo + Trastuzumab + DocetaxelTotal
Female402404806
Male022
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pertuzumab + Trastuzumab + DocetaxelPlacebo + Trastuzumab + DocetaxelTotal
Hispanic or Latino394483
Not Hispanic or Latino362362724
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pertuzumab + Trastuzumab + DocetaxelPlacebo + Trastuzumab + DocetaxelTotal
American Indian or Alaska Native347
Asian128133261
Native Hawaiian or Other Pacific Islander000
Black or African American102030
White245235480
More than one race000
Unknown or Not Reported161430
Region
Region(Participants)Pertuzumab + Trastuzumab + DocetaxelPlacebo + Trastuzumab + DocetaxelTotal
Asia125128253
Europe154152306
North America6768135
South America5658114
Prior Treatment Status
Prior Treatment Status(Participants)Pertuzumab + Trastuzumab + DocetaxelPlacebo + Trastuzumab + DocetaxelTotal
Adjuvant or Neo-Adjuvant Therapy184192376
De Novo218214432
Independent-Review Facility (IRF)-Determined Disease Status at Screening
Independent-Review Facility (IRF)-Determined Disease Status at Screening(Participants)Pertuzumab + Trastuzumab + DocetaxelPlacebo + Trastuzumab + DocetaxelTotal
Measurable Disease343336679
Non-Measurable Disease444387
Not Evaluated152742
08

Study locations

322 sites
  • HonorHealth Research Institute - Bisgrove
    Scottsdale, Arizona 85258, United States
  • NEA Baptist Clinic
    Jonesboro, Arkansas 72401, United States
  • Central Hematology Oncology Medical Group Inc.
    Alhambra, California 91801, United States
  • Pacific Cancer Medical Center
    Anaheim, California 92801, United States
  • Comprehensive Blood/Cancer Ctr
    Bakersfield, California 93309, United States
  • Kaiser Permanente - Baldwin Park
    Baldwin Park, California 91706, United States
  • Tower Cancer Research Foundation
    Beverly Hills, California 90211, United States
  • South Bay Oncology Hematology Partners
    Campbell, California 95008, United States
  • Wilshire Oncology Medical Group
    Corona, California 92879, United States
  • Compassionate Cancer Care
    Fountain Valley, California 92708, United States
  • Pacific Coast Hematology/Oncology Medical Group
    Fountain Valley, California 92708, United States
  • St. Jude Heritage Healthcare; Virgiia K.Crosson Can Ctr
    Fullerton, California 92835, United States
  • Wilshire Onc Med Grp., Inc
    Glendora, California 91741, United States
  • Wilshire Oncology Medical Group
    La Verne, California 91750, United States
  • UCLA
    Los Angeles, California 90024, United States
  • LAC USC Medical Center
    Los Angeles, California 90033, United States
  • Cedars- Sinai Medical Center
    Los Angeles, California 90048, United States
  • Ronald Reagan UCLA Medical Center Clin Lab
    Los Angeles, California 90095, United States
  • TORI Central Administration
    Los Angeles, California 90095, United States
  • UCLA Hematology / Oncology Clinic
    Los Angeles, California 90095, United States
  • UCLA Med Ctr; Pharma Svcs
    Los Angeles, California 90095, United States
  • Sutter Gould Medical Foundation; Clinical Research
    Modesto, California 95355, United States
  • Kaiser Permanente - Oakland
    Oakland, California 94611, United States
  • Ventura County Hematology-Oncology Specialists
    Oxnard, California 93030, United States
  • UCLA Healthcare/Pasadena Oncology
    Pasadena, California 91105, United States
  • Wilshire Oncology Medical Group
    Pasadena, California 91750, United States
  • Bay Area Cancer Research Group, LLC
    Pleasant Hill, California 94523, United States
  • Wilshire Oncology Medical Group
    Pomona, California 91767, United States
  • Wilshire Oncology Medical Group
    Rancho Cucamonga, California 91730, United States
  • UC Davis Cancer Center; Oncology
    Sacramento, California 95817, United States
  • Kaiser Permanente San Diego; Hepatology Research
    San Diego, California 92154, United States
  • K. Permanente - San Fransisco
    San Francisco, California 94115, United States
  • K. Permanente - San Jose
    San Jose, California 95119, United States
  • Sansum Santa Barbara Medical Foundation Clinic
    Santa Barbara, California 93105, United States
  • Santa Barbara Hematology Oncology Medical Group, Inc.
    Santa Barbara, California 93105, United States
  • UCLA Hematology/Oncology
    Santa Monica, California 90404, United States
  • UCLA / Santa Clarita Valley Cancer Center
    Valencia, California 91355, United States
  • Kaiser Permanente - Vallejo
    Vallejo, California 94589, United States
  • K. Permanente - Walnut Creek
    Walnut Creek, California 94596, United States
  • Wilshire Oncology Medical Group
    West Covina, California 91790, United States
  • Innovative clinical research institute/American institute of research
    Whittier, California 90603, United States
  • Georgetown University Medical Center Lombardi Cancer Center
    Washington, District of Columbia 20007, United States
  • MedStar Washington Hosp Center
    Washington, District of Columbia 20010, United States
  • Sibley Memorial Hospital
    Washington, District of Columbia 20016, United States
  • Boca Raton Comprehensive Cancer Center
    Boca Raton, Florida 33428, United States
  • Florida Cancer Specialists -Cape Coral (Cape Coral Pkwy)
    Cape Coral, Florida 33914, United States
  • Florida Cancer Specialists - Cape Coral (Del Prado Blvd)
    Cape Coral, Florida 33990, United States
  • Northwest Oncology/ Hematology Assoc.
    Coral Springs, Florida 33065-5701, United States
  • UM Sylvester Deerfield Beach; Sylvester Cancer Ctr
    Deerfield Beach, Florida 33442, United States
  • Florida Cancer Specialists - Englewood
    Englewood, Florida 34223, United States
  • Florida Cancer Specialists - Fort Myers (New Hampshire Ct)
    Fort Myers, Florida 33901-8101, United States
  • Florida Cancer Specialists - Broadway
    Fort Myers, Florida 33901, United States
  • Florida Cancer Specialists; SCRI
    Fort Myers, Florida 33901, United States
  • Florida Cancer Specialists-Broadway, Fort Myers
    Fort Myers, Florida 33908, United States
  • Private Practice Robert R. Carroll, Md, Pa
    Gainesville, Florida 32605, United States
  • Memorial Cancer Institute
    Hollywood, Florida 33021, United States
  • Memorial Regional Hospital
    Hollywood, Florida 33021, United States
  • Lakeland Regional Cancer Center
    Lakeland, Florida 33804-1057, United States
  • Jackson Memorial Hospital
    Miami, Florida 33136, United States
  • University of Miami School of Medicine
    Miami, Florida 33136, United States
  • Florida Cancer Specialists - Goodlette, Naples
    Naples, Florida 34102, United States
  • Florida Cancer Specialists - Pine Ridge, Naples
    Naples, Florida 34119, United States
  • Private Practice
    Orlando, Florida 32804, United States
  • Breast Cancer Centre at Memorial Hospital West
    Pembroke Pines, Florida 33028, United States
  • Florida Cancer Specialists - Port Charlotte
    Port Charlotte, Florida 33980, United States
  • Florida Cancer Specialists; Sarasota
    Sarasota, Florida 34232, United States
  • Bay Area Oncology
    Tampa, Florida 33607, United States
  • Florida Cancer Specialists - Venice (S. Tamiami Tr)
    Venice, Florida 33980, United States
  • Florida Cancer Specialists - Sunset Lake, Venice
    Venice, Florida 34292, United States
  • Cleveland Clinic Florida
    Weston, Florida 33331, United States
  • Northeast Georgia Medical Center; Oncology Research Dept-5C
    Gainesville, Georgia 30501, United States
  • Central Georgia Hematology Oncology Associates
    Macon, Georgia 31201, United States
  • Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital
    Marietta, Georgia 30060, United States
  • Central GA Cancer Care
    Warner Robins, Georgia 31088-2259, United States
  • Elmhurst Hospital
    Elmhurst, Illinois 60126, United States
  • Hematology Oncology Consultants Ltd
    Naperville, Illinois 60540, United States
  • Quincy Medical Group
    Quincy, Illinois 62301, United States
  • Midwestern Regional Medical Center; Office of Research
    Zion, Illinois 60099, United States
  • Monroe Medical Associates - Hobart
    Hobart, Indiana 46342, United States
  • St. Mary Medical Center
    Hobart, Indiana 46432, United States
  • Hematology-Oncology of Indiana, Pc
    Indianapolis, Indiana 46260, United States
  • Community Hospital; Pharmacy
    Munster, Indiana 46321, United States
  • Northwest Oncology
    Munster, Indiana 46321, United States
  • Monroe Medical Associates
    Munster, Indiana 46375, United States
  • Family Medicine Vincennes
    Vincennes, Indiana 47591, United States
  • Uni of Iowa Hospital&Clinic; Holden Comprehens. Cancer Ctr
    Iowa City, Iowa 52242, United States
  • University of Kansas; Medical Center & Medical pavilion
    Westwood, Kansas 66205, United States
  • Cancer Center of Kansas
    Wichita, Kansas 67214-3728, United States
  • Jewish Cancer Care
    Louisville, Kentucky 40245, United States
  • Cancer Center of Acadiana at Lafayette General
    Lafayette, Louisiana 70506, United States
  • Christus Schumpert Health System
    Shreveport, Louisiana 71101-1978, United States
  • Private Practice- Carolyn Hendricks, MD
    Bethesda, Maryland 20817, United States
  • Boston Medical Center
    Boston, Massachusetts 02118-2393, United States
  • Berkshire Hematology, Oncology Pc
    Pittsfield, Massachusetts 01201, United States
  • Cancer & Hematology Centers of Western Michigan
    Grand Rapids, Michigan 49503, United States
  • Cancer & Hematology Center of West Michigan
    Grand Rapids, Michigan 49546, United States
  • Oncology Care Associates PLLC
    Saint Joseph, Michigan 49085, United States
  • Southdale Cancer Clinic U of M Medical Center, Fairview- Edina
    Edina, Minnesota 55435, United States
  • US Oncology Research at Minnesota Oncology
    Minneapolis, Minnesota 55404, United States
  • Minneapolis Oncology Hamatology PA
    Minneapolis, Minnesota 55407-3799, United States

Showing the first 100 of 322 sites across 26 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012 Jan 12;366(2):109-19. doi: 10.1056/NEJMoa1113216. Epub 2011 Dec 7. PubMed 22149875 ↗
  • Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortes J; CLEOPATRA study group. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020 Apr;21(4):519-530. doi: 10.1016/S1470-2045(19)30863-0. Epub 2020 Mar 12. PubMed 32171426 ↗
  • Miles D, Im YH, Fung A, Yoo B, Knott A, Heeson S, Beattie MS, Swain SM. Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial. Ann Oncol. 2017 Nov 1;28(11):2761-2767. doi: 10.1093/annonc/mdx406. PubMed 29112701 ↗
  • Swain SM, Schneeweiss A, Gianni L, Gao JJ, Stein A, Waldron-Lynch M, Heeson S, Beattie MS, Yoo B, Cortes J, Baselga J. Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. Ann Oncol. 2017 Apr 1;28(4):761-768. doi: 10.1093/annonc/mdw695. Erratum In: Ann Oncol. 2018 Apr 1;29(4):1075. doi: 10.1093/annonc/mdx336. Ann Oncol. 2018 Jul 1;29(7):1607. doi: 10.1093/annonc/mdx802. Ann Oncol. 2019 Aug 1;30(8):1404. doi: 10.1093/annonc/mdy538. PubMed 28057664 ↗
  • Luen SJ, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E, Kiermaier A, Swain SM, Baselga J, Michiels S, Loi S. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol. 2017 Jan;18(1):52-62. doi: 10.1016/S1470-2045(16)30631-3. Epub 2016 Dec 7. Erratum In: Lancet Oncol. 2018 Dec;19(12):e667. doi: 10.1016/S1470-2045(18)30850-7. PubMed 27964843 ↗
  • Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortes J; CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015 Feb 19;372(8):724-34. doi: 10.1056/NEJMoa1413513. PubMed 25693012 ↗
  • Baselga J, Cortes J, Im SA, Clark E, Ross G, Kiermaier A, Swain SM. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol. 2014 Nov 20;32(33):3753-61. doi: 10.1200/JCO.2013.54.5384. Epub 2014 Oct 20. PubMed 25332247 ↗
  • Swain SM, Baselga J, Miles D, Im YH, Quah C, Lee LF, Cortes J. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol. 2014 Jun;25(6):1116-21. doi: 10.1093/annonc/mdu133. Epub 2014 Mar 31. PubMed 24685829 ↗
  • Miles D, Baselga J, Amadori D, Sunpaweravong P, Semiglazov V, Knott A, Clark E, Ross G, Swain SM. Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). Breast Cancer Res Treat. 2013 Nov;142(1):89-99. doi: 10.1007/s10549-013-2710-z. Epub 2013 Oct 16. PubMed 24129974 ↗
  • Cortes J, Baselga J, Im YH, Im SA, Pivot X, Ross G, Clark E, Knott A, Swain SM. Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Ann Oncol. 2013 Oct;24(10):2630-2635. doi: 10.1093/annonc/mdt274. Epub 2013 Jul 17. PubMed 23868905 ↗
  • Swain SM, Kim SB, Cortes J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013 May;14(6):461-71. doi: 10.1016/S1470-2045(13)70130-X. Epub 2013 Apr 18. PubMed 23602601 ↗
  • Baselga J, Swain SM. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Clin Breast Cancer. 2010 Dec 1;10(6):489-91. doi: 10.3816/CBC.2010.n.065. PubMed 21147694 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2008 to primary completion in May 2011, 39 months.

Results were first posted in Sep 2012, 1 year 4 months after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 39 months is close to that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2007
First posted
Dec 4, 2007
StartActual
Feb 12, 2008
Primary completionActual
May 13, 2011
CompletionActual
Nov 23, 2018
Results first posted
Sep 13, 2012
Last update
Dec 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00567190
Lead sponsor
Genentech, Inc.
Collaborators
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 4, 2007
Start date
Feb 12, 2008
Primary completion
May 13, 2011
Completion
Nov 23, 2018
Results posted
Sep 13, 2012
Last update
Dec 13, 2019

Study contacts

Clinical Trials
study director · Genentech, Inc./Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pertuzumab

Start the discussion